Services on Demand
Journal
Article
Indicators
Cited by SciELO
Access statistics
Related links
Similars in SciELO
Share
Gen
Print version ISSN 0016-3503
Abstract
PAEZ, Rosela; AURE, Carmen and ROMERO, Adriana. Efficacy of ursodeoxycholic acid in the treatment of nonalcoholic fatty liver disease. Gen [online]. 2012, vol.66, n.4, pp.224-227. ISSN 0016-3503.
Introduction: Estimated prevalence of Non-Alcoholic Fatty Liver Disease (NALFD) ranges from 10 % to 24 % of the general population. The history natural is poorly unknown for focused therapeutic options. Ursodeoxycholic Acid (UDCA) has long been used in the chronic cholestatic liver diseases, in NALFD believed to have cytoprotective properties and may help to reduce oxidative stress. Objetive: to know the efficacy of UDCA for improvement the serum aminotransferase levels (ALT). Patients and Methods: a prospective, experimental study was performed between january 2009 and december 2011 all patients with elevated ALT were included received UDCA 13 mg/kg/daily for 12 weeks. Analyses were conducted using Kolmogorov-Smirnov and chi-squared test with p<0,001 and p<0,05 was considered as the level of significance respectively. Results: a total of 53 patients, 55 % were female with a mean of 47,1 years old (DS±13,7 years). To compare the mean of ALT among the patients underwent starting treatment before and after was 122,3 U/L y 64,7 U/L respectively and statistically significant p<0,001 and the mean of ALT female gender was rate of response showed difference in patients 110,9 U/L y 53,13 U/L and male gender was 136 U/L y 78,7 U/L before and after UDCA was statistically significant p<0,001. Rate of response did differ in patients treated with UDCA 4, 8 and 12 weeks was 34,8 %, 30 % y 80 % respectively being statistically significant p<0,05 % at 12 weeks. Conclusion: at the present study we determined that UDCA was effective, in a given time, for improvement the serum aminotransferase levels.
Keywords : Non-Alcoholic Fatty Liver Disease; Ursodeoxycholic Acid; Aminotransferase.